The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.m

Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

Publications

Umemura S, Yamane H, Suwaki T, Katoh T, Yano T, Shiote Y, Takigawa N, Kiura K, Kamei H

Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.

Journal of cancer research and clinical oncology 2011 Oct;137;1469-75 — 2011 Oct — 1469-75

Maniwa K, Tanaka E, Inoue T, Kato T, Sakuramoto M, Minakuchi M, Maeda Y, Noma S, Kobashi Y, Taguchi Y

An autopsy case of acute pulmonary toxicity associated with gemcitabine.

Internal medicine (Tokyo, Japan) 2003 Oct;42;1022-5 — 2003 Oct — 1022-5

Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL

Diffuse alveolar damage in a patient treated with gemcitabine.

The European respiratory journal 1998 Feb;11;504-6 — 1998 Feb — 504-6

Pavlakis N, Bell DR, Millward MJ, Levi JA

Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Cancer 1997 Jul 15;80;286-91 — 1997 Jul 15 — 286-91